Key Publications

  • Okada Y, Nishiwada S, Yamamura K, Sho M, Baba H, Takayama T and Goel A (2021). Identification of LAMC2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. European Journal of Cancer, (In Press).
  • Lee IS, Lee H, Hur H, Kanda M, Yook JH, Kim BS, Woo Y, Kodera Y, Kim KS and Goel A (2021). Transcriptomic profiling identifies a risk stratification signature for predicting peritoneal recurrence and micrometastasis in patients with gastric cancer. Clinical Cancer Research, (In Press).
  • Crichton DJ, Altinok A, Amos C, Anton K, Cinquini L, Colbert M, Feng Z, Goel A, Kelly S, Kincaid S, Liu D, Lomeyda S, Mahabal A, Patriotis C and Srivastava S (2020). Cancer biomarkers and big data: A planetary science approach. Cancer Cell, 38(6): 757-760. [Epub ahead of print]; PMID: 32976775.
  • Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H and Goel A (2020). A microRNA signature identified pancreatic ductal adenocarcinoma patients at risk for lymph node metastases. Gastroenterology, 159(2): 562-574. PMID: 32376411.
  • Jung G, Hernandez-Illa E, Moreira L, Balaguer F and Goel A (2020). Epigenetics of colorectal cancer: Biomarker and therapeutic potential. Nature Reviews Gastroenterology and Hepatology, 17(2): 111-130. PMID: 31900466. PMCID: PMC7228650.
  • Kandimalla R, Shimura T, Mallik S, Sonohara F, Tsai S, Evans DB, Kim SC, Baba H, Kodera Y, Von Hoff D, Chen X and Goel A (2020). Identification of serum miRNA signature and establishment of a nomogram for risk-stratification in patients with pancreatic ductal adenocarcinoma. Annals of Surgery, [Epub ahead of print]; PMID:32398486.
  • Kandimalla R, Gao F, Li Y, Huang H, Ke J, Deng X, Zhao L, Zhou S, Goel A* and Wang X (2019). RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level.  NPJ Precision Oncology, 3:13. PMID: 31069256. PMCID: PMC6494854.
  • Ruiz-Banobre J, Kandimalla R and Goel A (2019). Predictive biomarkers for therapeutic response in metastatic colorectal cancer: A systematic review. JCO Precision Oncology, 156(4): 890-903. PMID: 32914007. PMCID: PMC7446314.
  • Kandimalla R, Ozawa T, Gao F, Nozawa H, Hata K, Nagata H, Okada S, Izumi D, Baba H, Watanabe T, Fleshman J, Pellise M, Bujanda L, Cuatrecasas M, Balaguer F, Wang X and Goel A (2019). Gene expression signature in surgical tissues and endoscopic biopsies identifies high-risk T1 colorectal cancers. Gastroenterology, 156(8):2338-2341.  PMID: 30797795. PMCID: PMC6538250.   
  • Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra C, Kopetz S, Wang X and Goel A (2018). Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer. Clinical Cancer Research, 24(16): 3867-3877. PMID: 29514841. PMCID: PMC6095767.
  • Weng W, Liu N, Toiyama Y, Kusunoki M, Nagasaka T, Fujiwara T, Wei Q, Qin H, Lin H, Ma Y and Goel A (2018). Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential diagnostic biomarker in colorectal cancer. Molecular Cancer, 17(1): 16. PMID: 29382334. PMCID: PMC5791351. 
  • Ozawa T, Kandimalla R, Gao F, Nozawa H, Hata K, Nagata H, Okada S, Izumi D, Baba H, Fleshman J, Wang X, Watanabe T and Goel A (2018). A microRNA signature associated with metastasis of T1 colorectal cancers to lymph nodes. Gastroenterology, 154(4):844-848. PMID: 29199088. PMCID: PMC5847452.
  • Toiyama Y, Okugawa Y, Tanaka K, Araki T, Uchida K, Hishida A, Uchino M, Ikeuchi H, Hirota S, Kusunoki M, Boland CR and Goel A (2017). A panel of methylated microRNA biomarkers for identifying high-risk patients with Ulcerative colitis-associated colorectal cancer. Gastroenterology, 153(6): 1634-1646; PMID: 28847750. PMCID: PMC28847750.
  • Weng W, Wei Q, Toden S, Yoshida K, Nagasaka T, Fujiwara T, Cai S, Qin H, Ma Y and Goel A (2017). Circular RNA ciRS-7: A promising prognostic biomarker and a potential therapeutic target in colorectal cancer. Clinical Cancer Research, 23(14): 3918-3928. PMID: 28174233. PMCID: PMC5511556.
  • Ozawa T, Matsuyama T, Toiyama Y, Takahashi N, Ishikawa T, Uetake H, Yamada Y, Kusunoki M, Calin G and Goel A (2017). CCAT1 and CCAT2 long noncoding RNAs, located within the 8q24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancer. Annals of Oncology, 28(8): 1882-1888. PMID: 28838211. PMCID: PMC5834045.
  • Hur K, Toiyama Y, Okugawa Y, Ide S, Imaoka H, Boland CR and Goel A (2017). Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut, 66(4): 654-665. PMID: 26701878. PMCID: PMC4919275.
  • Boland CR and Goel A (2016). Prognostic subgroups among patients with stage II colon cancer. NEJM: New England Journal of Medicine, 374(3): 277-278. PMID: 26789877. PMCID: PMC4852473. 
  • Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR and Goel A (2015). Identification of a metastasis-specific microRNA signature in human colorectal cancer. JNCI: Journal of National Cancer Institute, 107(3): 1-11. PMID: 25663689. PMCID: PMC4334826. 
  • Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusonoki M, Boland CR and Goel A (2013). Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. JNCI: Journal of National Cancer Institute, 105(12): 849-859. PMID: 23704278. PMCID: PMC3687369. 
  • Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A (2013). MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut, 62(9): 1315-1326. PMID: 22735571. PMCID: PMC3787864. 
  • Goel A and Boland CR (2012). Epigenetics of colorectal cancer. Gastroenterology, 143(6): 1442-1460. PMID: 23000599. PMCID: PMC3611241. 
  • Goel A, Nagasaka T, Spiegel J, Meyer R, Lichliter WE and Boland CR (2010). Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Clinical Gastroenterology and Hepatology, 8(11): 966-971. PMID: 20655395. PMCID: PMC2964436.
  • Nagasaka T, Tanaka N, Cullings HM, Sun DS, Sasamoto H, Uchida T, Koi M, Nishida N, Namomoto Y, Boland CR, Matsubara N and Goel A (2009). Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. JNCI: Journal of National Cancer Institute, 101(18): 1244-1258. PMID: 19700653. PMCID: PMC2762745.
  • Goel A, Kunnumakkara AB and Aggarwal BB (2008). Curcumin as “Curecumin”: From kitchen to clinic. Biochemical Pharmacology, 75(4): 787-809. PMID: 17900536.
  • Shin SK, Nagasaka T, Jung BH, Matsubara N, Kim WH, Carethers JM, Boland CR and Goel A (2007). Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology, 133(6): 1849-1857. PMID: 18054557. PMCID: PMC4139066.
  • Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM and Boland CR. (2007). The CpG Island Methylator Phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology, 132(1): 127-138. PMID: 17087942.
  • Gasche C, Chang CL, Natarajan L, Goel A, Rhees J, Young DJ, Arnold CN, and Boland CR. (2003). Identification of frame-shift Intermediate Mutant Cells. PNAS: Proceedings of National Academy of Sciences USA, 100 (4): 1914-1919. PMID: 12578960. PMCID: PMC149933.
  • Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM and Boland CR. (2003). Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Research, 63(7): 1608-1614. PMID: 12670912.